I.5 Does the human uterus agree with existing models? Experiences with insulin-like growth factor (IGF)

European Journal of Cancer

Volumn 34, Issue SUPPL. 4, 1998, Pages

  Tomas E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; TAMOXIFEN;

BREAST CANCER; CANCER PATIENT; CELL PROLIFERATION; CONFERENCE PAPER; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; HORMONAL REGULATION; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0031669443     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00088-4     Document Type: Conference Paper

References (4)

1. Rutanen E-M, Seppälä M. Insulin-like growth factor binding protein-1 in female reproductive functions. Int J Gynaecol Obstet 1992, 39, 3-9.
2. Pollak MN, Huynh HT, Lefebvre SP. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 1992, 22, 91-100.
3. Giudice LC, Dsupin BA, Jin IH, Vu TH, Hoffman AR. Differential expression of mRNAs encoding insulin-like growth factors and their receptors in human uterine endometrium and decidua. J Clin Endocrinol Metab 1993, 76, 1115-1122.
4. Rutanen E-M, Nyman T, Lehtovirta P, Ämmala M, Pekonen F. Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer 1994, 59, 307-312.